SCHEMBL22728558

SCHEMBL22728558

Cc1ccc(-c2csc(NC(=O)c3ccncn3)n2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPL P40238 5/20 0.69
MAPT P10636 3/20 0.61
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
POLB P06746 2/20 0.61
ALDH1A1 P00352 1/20 0.61
ESR1 P03372 1/20 0.61
ESR2 Q92731 1/20 0.61
HSD17B10 Q99714 1/20 0.61
LMNA P02545 3/20 0.60
NPC1 O15118 3/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
KDM4E B2RXH2 2/20 0.60
RAB9A P51151 2/20 0.60
HTT P42858 2/20 0.59
CDC25A P30304 1/20 0.58
CDC25B P30305 1/20 0.58
CDC25C P30307 1/20 0.58
GSTO1 P78417 1/20 0.57
ROCK2 O75116 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12249047 0.89 MEN1 (0.59) MPLMAPTMEN1KMT2APOLB
SCHEMBL22728498 0.85 LMNA (0.78) MPLMAPTMEN1KMT2APOLB
SCHEMBL12249012 0.85 MPL (0.60) MPLMEN1KMT2ALMNANPC1
SCHEMBL12248896 0.85 ADORA3 (0.68) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL22728560 0.84 MEN1 (0.62) MPLMAPTMEN1KMT2APOLB
SCHEMBL12248876 0.84 PARP1 (0.76) MPLMAPTMEN1KMT2APOLB
SCHEMBL22728481 0.84 LMNA (0.64) MPLMAPTMEN1KMT2APOLB
SCHEMBL12248874 0.83 SMN1; SMN2 (0.54) MPLMAPTMEN1KMT2APOLB
SCHEMBL1883429 0.82 PARP1 (0.74) MPLMAPTMEN1KMT2APOLB
SCHEMBL4872388 0.82 MPL (1.00) MPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 US disclosed
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 US disclosed
US-11420964-B2 Compositions and methods for modulating inflammatory and degenerative disorder UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2022-08-23 US disclosed
WO-2022082071-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF US THEREOF CARTHRONIX, INC. (US) 2022-04-21 WO disclosed
US-20220048901-A1 COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER UNIVERSITY OF SOUTHERN CALIFORNIA 2022-02-17 US disclosed
US-20200377494-A1 COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER UNIVERSITY OF SOUTHERN CALIFORNIA 2020-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF STAT1, STAT3, STAT6 MPL 249/4885MAPT 4065/4885MEN1 4814/4885
US-11420964-B2 Compositions and methods for modulating inflammatory and degenerative disorder TNF, MSR1, GRN MPL 666/4885MAPT 2213/4885MEN1 4606/4885
US-20220048901-A1 COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER TNF, MSR1, GRN MPL 666/4885MAPT 2213/4885MEN1 4606/4885
US-20200377494-A1 COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER TNF, MSR1, GRN MPL 666/4885MAPT 2213/4885MEN1 4606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.